ARTICLE | Clinical News

FDA accepts Scilex's resubmitted NDA for ZTlido

September 15, 2017 8:28 PM UTC

FDA accepted for review a resubmitted NDA from Scilex Pharmaceuticals Inc. (West Chester, Pa.) for ZTlido 1.8% lidocaine patch to treat postherpetic neuralgia (PHN). The PDUFA date is Feb. 28, 2018. Scilex is a majority owned subsidiary of Sorrento Therapeutics Inc. (NASDAQ:SRNE)...